İnflamatuar Meme Kanseri
Özet
İnflamatuar meme kanseri (İMK), tüm meme kanseri vakalarının yaklaşık %1-5'ini oluşturan, agresif ve lokal olarak ilerlemiş bir alt tiptir. Hastalık; memede kızarıklık, şişlik ve ısı artışı gibi mastit benzeri semptomlarla hızla progrese olur. Genellikle 55-59 yaş aralığında teşhis edilen İMK; kadınlarda, Afro-Amerikalılarda ve yüksek vücut kitle indeksine sahip bireylerde daha sık görülür. Çoğunlukla hormon reseptörlerinden yoksun ve HER2 pozitif bir tümör yapısına sahiptir. Metastatik olmayan vakalarda neoadjuvan kemoterapi, cerrahi ve adjuvan radyoterapiden oluşan "trimodal tedavi" standart yaklaşımdır. Rezeke edilemeyen hastalarda ise standart dışı tedavi stratejileri izlenir. Erken nüks riski yüksek ve prognozu kötü olan bu hastalık, düşük genel sağkalım oranları nedeniyle tıbbi onkolog, cerrah ve radyasyon onkoloğunun yer aldığı multidisipliner bir kurul tarafından yönetilmelidir.
Inflammatory breast cancer (IBC) is an aggressive and locally advanced subtype that accounts for approximately 1-5% of all breast cancer cases. The disease progresses rapidly, presenting with mastitis-like symptoms such as erythema, edema, and increased warmth in the breast. Typically diagnosed in the 55-59 age range, IBC occurs more frequently in women, African-Americans, and individuals with a high body mass index. It usually exhibits a tumor profile lacking hormone receptor expression and displaying HER2 amplification. For non-metastatic cases, the standard approach is "trimodal therapy," which comprises neoadjuvant chemotherapy, surgery, and adjuvant radiotherapy. In unresectable patients, a treatment approach similar to non-IBC patients is generally implemented. Associated with a high risk of early recurrence and poor prognosis, this disease requires management by a multidisciplinary team including medical oncologists, surgeons, and radiation oncologists due to lower overall survival rates.
Referanslar
Kalli S, Semine A, Cohen S, et al. American Joint Committee on Cancer's Staging System for Breast Cancer, Eighth Edition: What the Radiologist Needs to Know. Radiographics : a review publication of the Radiological Society of North America, Inc. 2018;38(7):1921-1933.doi.10.1148/rg.2018180056
Dawood S. Biology and management of inflammatory breast cancer. Expert review of anticancer therapy. 2010;10(2):209-220.doi.10.1586/era.09.90
Chainitikun S, Saleem S, Lim B, et al. Update on systemic treatment for newly diagnosed inflammatory breast cancer. Journal of advanced research. 2021;29:1-12.doi.10.1016/j.jare.2020.08.014
Abraham HG, Xia Y, Mukherjee B, et al. Incidence and survival of inflammatory breast cancer between 1973 and 2015 in the SEER database. Breast cancer research and treatment. 2021;185(1):229-238.doi.10.1007/s10549-020-05938-2
Hance KW, Anderson WF, Devesa SS, et al. Trends in inflammatory breast carcinoma incidence and survival: the surveillance, epidemiology, and end results program at the National Cancer Institute. Journal of the National Cancer Institute. 2005;97(13):966-975.doi.10.1093/jnci/dji172
Goldner B, Behrendt CE, Schoellhammer HF, et al. Incidence of inflammatory breast cancer in women, 1992-2009, United States. Annals of surgical oncology. 2014;21(4):1267-1270.doi.10.1245/s10434-013-3439-y
Boussen H, Bouzaiene H, Ben Hassouna J, et al. Inflammatory breast cancer in Tunisia: reassessment of incidence and clinicopathological features. Seminars in oncology. 2008;35(1):17-24.doi.10.1053/j.seminoncol.2007.11.017
Levine PH, Veneroso C. The epidemiology of inflammatory breast cancer. Seminars in oncology. 2008;35(1):11-16.doi.10.1053/j.seminoncol.2007.11.018
Soliman AS, Schairer C. Considerations in setting up and conducting epidemiologic studies of cancer in middle- and low-income countries: the experience of a case-control study of inflammatory breast cancer in North Africa in the past 10 years. Cancer medicine. 2012;1(3):338-349.doi.10.1002/cam4.36
Robertson FM, Bondy M, Yang W, et al. Inflammatory breast cancer: the disease, the biology, the treatment. CA: a cancer journal for clinicians. 2010;60(6):351-375.doi.10.3322/caac.20082
Chippa V, Barazi H. Inflammatory Breast Cancer. StatPearls. Treasure Island (FL) 2022.
Dahlbeck SW, Donnelly JF, Theriault RL. Differentiating inflammatory breast cancer from acute mastitis. American family physician. 1995;52(3):929-934
Blackmon MM, Nguyen H, Mukherji P. Acute Mastitis. StatPearls. Treasure Island (FL) 2022.
Le-Petross HT, Balema W, Woodward WA. Why diagnosing inflammatory breast cancer is hard and how to overcome the challenges: a narrative review. Chinese clinical oncology. 2021;10(6):58.doi.10.21037/cco-21-116
Le-Petross HT, Cristofanilli M, Carkaci S, et al. MRI features of inflammatory breast cancer. AJR American journal of roentgenology. 2011;197(4):W769-776.doi.10.2214/AJR.10.6157
Dawood S, Merajver SD, Viens P, et al. International expert panel on inflammatory breast cancer: consensus statement for standardized diagnosis and treatment. Annals of oncology : official journal of the European Society for Medical Oncology. 2011;22(3):515-523.doi.10.1093/annonc/mdq345
Patel MM, Le-Petross HT. Baseline FDG PET-CT imaging is necessary for newly diagnosed inflammatory breast cancer patients: a narrative review. Chinese clinical oncology. 2021;10(6):56.doi.10.21037/cco-21-82
Tanaka H, Hosono M, Kawabata K, et al. FDG-Avid Tracheal Mass and Cartilage Involvements in ANCA-Negative Granulomatosis With Polyangiitis. Clinical nuclear medicine. 2022;47(1):83-85.doi.10.1097/RLU.0000000000003848
Chow CK. Imaging in inflammatory breast carcinoma. Breast disease. 2005;22:45-54.doi.10.3233/bd-2006-22106
Calin MA, Elfarra FG, Parasca SV. Object-oriented classification approach for bone metastasis mapping from whole-body bone scintigraphy. Physica medica : PM : an international journal devoted to the applications of physics to medicine and biology : official journal of the Italian Association of Biomedical Physics. 2021;84:141-148.doi.10.1016/j.ejmp.2021.03.040
Pope WB. Brain metastases: neuroimaging. Handbook of clinical neurology. 2018;149:89-112.doi.10.1016/B978-0-12-811161-1.00007-4
Rueth NM, Lin HY, Bedrosian I, et al. Underuse of trimodality treatment affects survival for patients with inflammatory breast cancer: an analysis of treatment and survival trends from the National Cancer Database. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2014;32(19):2018-2024.doi.10.1200/JCO.2014.55.1978
Baldini E, Gardin G, Evagelista G, et al. Long-term results of combined-modality therapy for inflammatory breast carcinoma. Clinical breast cancer. 2004;5(5):358-363.doi.10.3816/cbc.2004.n.042
Ueno NT, Buzdar AU, Singletary SE, et al. Combined-modality treatment of inflammatory breast carcinoma: twenty years of experience at M. D. Anderson Cancer Center. Cancer chemotherapy and pharmacology. 1997;40(4):321-329.doi.10.1007/s002800050664
Harris EE, Schultz D, Bertsch H, et al. Ten-year outcome after combined modality therapy for inflammatory breast cancer. International journal of radiation oncology, biology, physics. 2003;55(5):1200-1208.doi.10.1016/s0360-3016(02)04201-3
Adesoye T, Lucci A. Current Surgical Management of Inflammatory Breast Cancer. Annals of surgical oncology. 2021;28(10):5461-5467.doi.10.1245/s10434-021-10522-z
Cristofanilli M, Gonzalez-Angulo AM, Buzdar AU, et al. Paclitaxel improves the prognosis in estrogen receptor negative inflammatory breast cancer: the M. D. Anderson Cancer Center experience. Clinical breast cancer. 2004;4(6):415-419.doi.10.3816/cbc.2004.n.004
Dano D, Lardy-Cleaud A, Monneur A, et al. Metastatic inflammatory breast cancer: survival outcomes and prognostic factors in the national, multicentric, and real-life French cohort (ESME). ESMO open. 2021;6(4):100220.doi.10.1016/j.esmoop.2021.100220
Gianni L, Pienkowski T, Im YH, et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. The Lancet Oncology. 2012;13(1):25-32.doi.10.1016/S1470-2045(11)70336-9
Baselga J, Cortes J, Kim SB, et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. The New England journal of medicine. 2012;366(2):109-119.doi.10.1056/NEJMoa1113216
Li J, Xia Y, Wu Q, et al. Outcomes of patients with inflammatory breast cancer by hormone receptor- and HER2-defined molecular subtypes: A population-based study from the SEER program. Oncotarget. 2017;8(30):49370-49379.doi.10.18632/oncotarget.17217
Zell JA, Tsang WY, Taylor TH, et al. Prognostic impact of human epidermal growth factor-like receptor 2 and hormone receptor status in inflammatory breast cancer (IBC): analysis of 2,014 IBC patient cases from the California Cancer Registry. Breast cancer research : BCR. 2009;11(1):R9.doi.10.1186/bcr2225
Curcio LD, Rupp E, Williams WL, et al. Beyond palliative mastectomy in inflammatory breast cancer--a reassessment of margin status. Annals of surgical oncology. 1999;6(3):249-254.doi.10.1007/s10434-999-0249-3
Perez CA, Fields JN, Fracasso PM, et al. Management of locally advanced carcinoma of the breast. II. Inflammatory carcinoma. Cancer. 1994;74(1 Suppl):466-476.doi.10.1002/cncr.2820741336
Panades M, Olivotto IA, Speers CH, et al. Evolving treatment strategies for inflammatory breast cancer: a population-based survival analysis. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2005;23(9):1941-1950.doi.10.1200/JCO.2005.06.233
Brun B, Otmezguine Y, Feuilhade F, et al. Treatment of inflammatory breast cancer with combination chemotherapy and mastectomy versus breast conservation. Cancer. 1988;61(6):1096-1103.doi.10.1002/1097-0142(19880315)61:6<1096::aid-cncr2820610608>3.0.co;2-y
Lyman GH, Giuliano AE, Somerfield MR, et al. American Society of Clinical Oncology guideline recommendations for sentinel lymph node biopsy in early-stage breast cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2005;23(30):7703-7720.doi.10.1200/JCO.2005.08.001
Stearns V, Ewing CA, Slack R, et al. Sentinel lymphadenectomy after neoadjuvant chemotherapy for breast cancer may reliably represent the axilla except for inflammatory breast cancer. Annals of surgical oncology. 2002;9(3):235-242.doi.10.1007/BF02573060
Kaidar-Person O, Poortmans P, Offersen BV, et al. Spatial location of local recurrences after mastectomy: a systematic review. Breast cancer research and treatment. 2020;183(2):263-273.doi.10.1007/s10549-020-05774-4
Liao Z, Strom EA, Buzdar AU, et al. Locoregional irradiation for inflammatory breast cancer: effectiveness of dose escalation in decreasing recurrence. International journal of radiation oncology, biology, physics. 2000;47(5):1191-1200.doi.10.1016/s0360-3016(00)00561-7
Motwani SB, Strom EA, Schechter NR, et al. The impact of immediate breast reconstruction on the technical delivery of postmastectomy radiotherapy. International journal of radiation oncology, biology, physics. 2006;66(1):76-82.doi.10.1016/j.ijrobp.2006.03.040
Fouad TM, Kogawa T, Liu DD, et al. Overall survival differences between patients with inflammatory and noninflammatory breast cancer presenting with distant metastasis at diagnosis. Breast cancer research and treatment. 2015;152(2):407-416.doi.10.1007/s10549-015-3436-x
Beslija S, Bonneterre J, Burstein HJ, et al. Third consensus on medical treatment of metastatic breast cancer. Annals of oncology : official journal of the European Society for Medical Oncology. 2009;20(11):1771-1785.doi.10.1093/annonc/mdp261
Liu J, Chen K, Jiang W, et al. Chemotherapy response and survival of inflammatory breast cancer by hormone receptor- and HER2-defined molecular subtypes approximation: an analysis from the National Cancer Database. Journal of cancer research and clinical oncology. 2017;143(1):161-168.doi.10.1007/s00432-016-2281-6
Li J, Gonzalez-Angulo AM, Allen PK, et al. Triple-negative subtype predicts poor overall survival and high locoregional relapse in inflammatory breast cancer. The oncologist. 2011;16(12):1675-1683.doi.10.1634/theoncologist.2011-0196
Hennessy BT, Gonzalez-Angulo AM, Hortobagyi GN, et al. Disease-free and overall survival after pathologic complete disease remission of cytologically proven inflammatory breast carcinoma axillary lymph node metastases after primary systemic chemotherapy. Cancer. 2006;106(5):1000-1006.doi.10.1002/cncr.21726
Hieken TJ, Murphy BL, Boughey JC, et al. Influence of Biologic Subtype of Inflammatory Breast Cancer on Response to Neoadjuvant Therapy and Cancer Outcomes. Clinical breast cancer. 2018;18(4):e501-e506.doi.10.1016/j.clbc.2017.10.003
Dawood S, Lei X, Dent R, et al. Survival of women with inflammatory breast cancer: a large population-based study. Annals of oncology : official journal of the European Society for Medical Oncology. 2014;25(6):1143-1151.doi.10.1093/annonc/mdu121
van Uden DJ, Bretveld R, Siesling S, et al. Inflammatory breast cancer in the Netherlands; improved survival over the last decades. Breast cancer research and treatment. 2017;162(2):365-374.doi.10.1007/s10549-017-4119-6
Gonzalez-Angulo AM, Hennessy BT, Broglio K, et al. Trends for inflammatory breast cancer: is survival improving? The oncologist. 2007;12(8):904-912.doi.10.1634/theoncologist.12-8-904
Menta A, Fouad TM, Lucci A, et al. Inflammatory Breast Cancer: What to Know About This Unique, Aggressive Breast Cancer. The Surgical clinics of North America. 2018;98(4):787-800.doi.10.1016/j.suc.2018.03.009
Biswas T, Efird JT, Prasad S, et al. Inflammatory TNBC Breast Cancer: Demography and Clinical Outcome in a Large Cohort of Patients With TNBC. Clinical breast cancer. 2016;16(3):212-216.doi.10.1016/j.clbc.2016.02.004
